epoetin-alfa has been researched along with Fibrosis* in 4 studies
1 review(s) available for epoetin-alfa and Fibrosis
Article | Year |
---|---|
Is the renoprotective effect of erythropoietin in chronic kidney disease a myth?
Topics: Animals; Epoetin Alfa; Erythropoietin; Fibrosis; Hematinics; Humans; Kidney; Recombinant Proteins; Renal Insufficiency, Chronic | 2013 |
3 other study(ies) available for epoetin-alfa and Fibrosis
Article | Year |
---|---|
The effect of simvastatin and erythropoietin on renal fibrosis in rats with unilateral ureteral obstruction.
Prevention of fibrosis is a very important therapeutic strategy in the treatment of obstructive nephropathy (ON). The aim of this study is to show and compare the actions of Simvastatin (Simv) and Erythropoietin (Epo) in renal expression of nuclear factor kappa B (NFκB), transforming growth factor-β (TGF-β), basic fibroblast growth factor (bFGF), platelet-derived growth factor B (PDGF-B), fibronectin and development of interstitial fibrosis in rats with unilateral ureteral obstruction (UUO). A total of 48 Sprague-Dawley rats were allocated to 4 groups of sham, Epo, Simv and control. Unilateral ureteral ligation was performed on all rats except the Sham group. For interstitial fibrosis Masson's trichrome stain and for the expression of TGF-β, PDGF-B, bFGF, NFκB and fibronectin, immunohistochemical methods were used. In the Epo and Simv groups, expression of TGF-β and fibronectin and staining with Masson's trichrome were less compared to the control group. In addition, fibronectin expression in the Epo group was less than the Simv group. Unlike the Simv group, NFκB and bFGF expression in the Epo group were less when compared to the control group. Consequently, it was seen that both Epo and Simv prevented fibrosis in ON. Epo was superior in this effect by suppressing the expressions of NFκB and bFGF more effectively than Simv. Based on this finding, Epo might be a better agent than Simv in the prevention of fibrosis in ON. Topics: Animals; Epoetin Alfa; Erythropoietin; Fibroblast Growth Factor 2; Fibronectins; Fibrosis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Kidney; Male; NF-kappa B; Proto-Oncogene Proteins c-sis; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Simvastatin; Transforming Growth Factor beta; Ureteral Obstruction | 2014 |
Increased progression to kidney fibrosis after erythropoietin is used as a treatment for acute kidney injury.
Treatment of renal ischemia-reperfusion (IR) injury with recombinant human erythropoietin (rhEPO) reduces acute kidney injury and improves function. We aimed to investigate whether progression to chronic kidney disease associated with acute injury was also reduced by rhEPO treatment, using in vivo and in vitro models. Rats were subjected to bilateral 40-min renal ischemia, and kidneys were studied at 4, 7, and 28 days postreperfusion for renal function, tubular injury and repair, inflammation, and fibrosis. Acute injury was modulated using rhEPO (1,000 or 5,000 IU/kg, intraperitoneally) at the time of reperfusion. Renal tubular epithelial cells or fibroblasts in culture were subjected to hypoxia or oxidative stress, with or without rhEPO (200 IU/ml), and fibrogenesis was studied. The results of the in vivo model confirmed functional and structural improvement with rhEPO at 4 days post-IR (P < 0.05). At 7 days post-IR, fibrosis and myofibroblast stimulation were increased with IR with and without rhEPO (P < 0.01). However, at 28 days post-IR, renal fibrosis and myofibroblast numbers were significantly greater with IR plus rhEPO (P < 0.01) compared with IR only. Mechanistically, rhEPO stimulated profibrotic transforming growth factor-β, oxidative stress (marker 8-hydroxy-deoxyguanosine), and phosphorylation of the signal transduction protein extracellular signal-regulated kinase. In vitro, rhEPO protected tubular epithelium from apoptosis but stimulated epithelial-to-mesenchymal transition and also protected and activated fibroblasts, particularly with oxidative stress. In summary, although rhEPO was protective of renal function and structure in acute kidney injury, the supraphysiological dose needed for renoprotection contributed to fibrogenesis and stimulated chronic kidney disease in the long term. Topics: Acute Kidney Injury; Animals; Apoptosis; Cells, Cultured; Disease Progression; Epoetin Alfa; Erythropoietin; Extracellular Signal-Regulated MAP Kinases; Fibrosis; Humans; Kidney; Kidney Diseases; Male; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Reperfusion Injury; Treatment Outcome | 2014 |
A 56-year-old woman with sarcoidosis and acute renal failure.
Topics: Acute Kidney Injury; Amlodipine; Epoetin Alfa; Erythropoietin; Female; Fibrosis; Humans; Inflammation; Middle Aged; Prednisone; Recombinant Proteins; Sarcoidosis; Treatment Outcome | 2008 |